Neuromodulation for Metabolic Dysfunction
Rahul Sachdeva · NCT07597161
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 120
- US sites recruiting
- 1
- Study start
- October 20, 2026
- Record last updated
- October 29, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study evaluates the use of noninvasive transcutaneous spinal cord stimulation (tSCS) to improve glucose regulation and metabolic function in individuals with and without spinal cord injury (SCI) across a spectrum of metabolic states, including no diabetes, prediabetes, and type 2 diabetes (T2D).
Being studied: Transcutaneous Spinal Cord Stimulation (tSCS); Sham transcutaneous spinal cord stimulation (tSCS)
Conditions: Spinal Cord Injuries (SCI); Prediabetes / Type 2 Diabetes
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participants must be at least 18 years of age and able to provide informed consent.
- Chronic spinal cord injury (at least 1 year post-injury) with neurological level of injury T6 or above, classified as AIS A-D, or able-bodied individuals without a history of spinal cord injury or neurological disorder
- Participants must meet criteria for normal glucose metabolism, prediabetes, or type 2 diabetes, determined using HbA1c, fasting plasma glucose, fasting insulin, or oral glucose tolerance testing (OGTT). Normal glucose metabolism is defined as HbA1c less than 5.7% and fasting plasma glucose less than or equal to 100 mg/dL. Impaired glucose metabolism (prediabetes or type 2 diabetes) will be identified by HbA1c greater than or equal to 5.7%, fasting plasma glucose greater than100 mg/dL (5.6 mmol/L), fasting insulin greater than 8.5-10 µIU/mL after at least 8 hours of fasting, or 2-hour plasma glucose greater than 140 mg/dL (7.8 mmol/L) during a standard OGTT performed using a 75 g anhydrous glucose load dissolved in water.
- Participants taking diabetes medications may be included if their medication regimen has been stable for at least 12 weeks before enrollment. This ensures observed metabolic changes are attributable to tSCS rather than recent medication adjustments. Medication use will be documented and included as a covariate in analyses to account for potential effects
Exclusion Criteria
- Unstable medical conditions (e.g., cardiac disease, active infections).
- Implanted devices (e.g., pacemakers, neurostimulators, ITB pumps).
- Change of medications that alter glucose metabolism (e.g., corticosteroids).
- Frequent, symptomatic hypoglycemia.
- Inability to tolerate stimulation procedures or complete study protocols.
- Diagnosis of Type 1 diabetes mellitus.
- Skin breakdown, eczema, or other dermatological conditions (e.g., psoriasis) affecting the skin at the site of electrodes placement.
- Females who are pregnant, breastfeeding, or intend to become pregnant.
- Cognitive impairments, social/psychological problems, or other comorbid conditions that, in the opinion of the Investigator, will preclude them from participation.
Recruiting US locations
Department of Physical Medicine and Rehabilitation-Research Suite
Lexington, KY 40504
Site contact: Vivek Pandey, PhD · 8593233933 · vivek.pandey@uky.edu
Study contacts (from the official record)
- Rahul Sachedva, PhD · 859-257-4888 · rsa327@uky.edu
- Vivek Pandey, PhD · 8593233933 · vivek.pandey@uky.edu
Similar studies in Kentucky
All diabetes studies in Kentucky →- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Edgewood, KY + 121 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals
- Location
- Lexington, KY + 20 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Lexington, KY + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
- Location
- Louisville, KY + 33 other US sites
- Eligibility basics
- Ages 1–25